港股異動 | 中國有贊大漲19% 周內股價已翻倍 前三季經營效率顯著提升
格隆匯11月17日丨中國有贊(8083.HK)尾盤快速拉昇漲超19%,周內股價已翻倍,現報0.214港元創4個月新高價,總市值39.2億港元。2022年前三季度,隨着更加聚焦的業務發展策略,以及不斷優化的組織架構和業務流程,中國有讚的經營效率取得了顯著提升。人均產出、經營現金流和經營結果都取得了顯著的改善。國盛證券維持中國有贊“買入”評級,聚焦核心客羣優化商家結構。該行預計,未來公司現金流及經營利潤將持續改善。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.